Highest-materiality recent filing
Theravance's ampreloxetine misses primary endpoint in Phase 3 CYPRESS nOH/MSA study
Primary endpoint (OHSA composite change at week 8 of randomized withdrawal) not statistically significant; secondary endpoints showed similar trends.
Net loss $5.9M vs net income $54.8M in Q2 2025 (2025 included $75.1M gain on TRELEGY royalty sale); non-GAAP ops income $9.5M vs loss $4.2M.
Theravance Biopharma to be acquired by Zymeworks for $17.00/share cash plus CVR
Shareholders receive $17.00/share cash (~$929M equity value) plus a CVR for 80% of net proceeds from ampreloxetine monetization over ten years.
Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled
YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).
Theravance settles YUPELRI patent suit; generic license start April 23, 2039
Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.
Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.
Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review
Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.
YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).
Enrollment completed in open-label portion of pivotal Phase 3 CYPRESS study (NCT05696717) for nOH due to MSA.
Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039
Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.
Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%
YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.
Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered
China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.
Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039
Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).
Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M
Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.
Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M
YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.
YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.
Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).
Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039
Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.
Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed
Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.
Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M
Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.
Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039
Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.
Q4 YUPELRI net sales recognized by Viatris grew 9% YoY to $60.6M record high; full-year Viatris collaboration revenue up 18% to $57.2M.
PIFR-2 study did not show statistically significant difference on primary endpoint (change in trough FEV1 at Day 85) for YUPELRI vs Spiriva HandiHaler.
Settlement Agreement with Accord resolves Hatch-Waxman litigation over YUPELRI inhalation solution.
Jeremy Grant appointed to Board as Class II director; Board temporarily expands to 10.
Q3 loss narrows to $9.0M; YUPELRI sales up 9%; SVP R&D to depart Feb 2024
GAAP net loss from continuing ops $9.0M vs $16.0M prior year; non-GAAP loss $0.7M (improved from $7.1M).
Theravance settles YUPELRI patent litigation with Teva; generic launch delayed to April 2039
Settlement with Teva resolves ANDA litigation; Teva gets license to launch generic on or after April 23, 2039.
Theravance Biopharma Q2 2023: YUPELRI sales up 12% YoY; $80.5M in share buybacks
YUPELRI net sales recognized by Viatris: $55.0M, up 12% YoY; Theravance's 35% share implies $19.3M.
Theravance Biopharma Q1 2023 net loss narrows to $22.1M; YUPELRI sales up 8% to $47M
Q1 GAAP net loss from continuing ops $22.1M vs $40.3M; non-GAAP net loss $14.9M vs $25.2M.
Theravance Biopharma increases buyback to $325M, announces formal strategic review
Capital Return Program increased to $325M; $170M remaining expected by end of 2023; $27M repurchased YTD 2023.
Theravance Biopharma upsizes buyback to $325M, cuts 17% staff, appoints new director
Capital return program increased to $325M; $170M remaining; $155M repurchased to date.
YUPELRI achieved all-time high net sales and profit in Q2 and Q3 2022; expects continued Q4 growth.
Theravance Biopharma completes sale of TRC units to Royalty Pharma for $1.107 billion cash
Sold 2,125 Class B and 6,375 Class C units of Theravance Respiratory Company to Royalty Pharma on July 20, 2022.
Theravance Biopharma Q3 2022: YUPELRI sales up 35% YoY; $1.1B TRELEGY deal closed; debt-free
Implied 35% share of YUPELRI net sales $18.7M, up 35% YoY; Viatris collaboration revenue $12.4M.
In connection with the Cooperation Agreement, the New Director was appointed to the Board, as well as the Development and Commercialization Committee and the Compensation Committee, each effective December 21, 2023.
In connection with internal changes at Theravance Biopharma, Inc., Richard Graham, Ph.D., Senior Vice President, Research & Development will be leaving the Company on or around February 29, 2024.
On April 11, 2023, James C. Kelly was appointed by the Board of Directors (the “Board”) of Theravance Biopharma, Inc. (the “Company”) to serve as a Class I member of the Board for a term expiring at the Company’s Annual General Meeting of Shareholders in 2024.
On January 10, 2023, Theravance Biopharma US, Inc., a wholly owned subsidiary of the Company (“Theravance Biopharma US”), and Mr. Hindman entered into a separation agreement and release of claims (the “Separation Agreement”).
In addition, on February 26, 2023, William D. Young decided not to stand for re-election as a director at the Company’s next annual general meeting of shareholders.
On February 26, 2023, Susannah Gray was appointed by the Board of Directors of Theravance Biopharma, Inc. (the “Company”) to serve as a Class II member of the Board of Directors.
Andrew A. Hindman, Senior Vice President and Chief Financial Officer, will transition from the Company on December 31, 2022.
The Company has appointed Aziz Sawaf, CFA as the Company’s Chief Financial Officer, effective immediately following Mr. Hindman’s departure.
On November 30, 2021, the Company and Mr. Sabesan entered into a consulting agreement to facilitate the transition of activities following Mr. Sabesan’s departure, pursuant to which certain outstanding equity awards will vest.
the Company and Mr. Shafer entered into a consulting agreement to facilitate the transition of activities following Mr. Shafer’s departure
Vijay Sabesan, Senior Vice President, Technical Operations, a “named executive officer” from 2021, will leave the Company on November 30, 2021.
Robert V. Gunderson, Jr. notified the Company of his resignation as a Director of the Company effective September 11, 2021
Max materiality 1.00 · Median 0.65 · Most common event other_material